Post by PharmaShots

Shanghai Junshi Biosciences Co Ltd licenses P-III anti-IL-17A antibody roconkibart to #FosunWanbang for Greater China development, manufacturing, and commercialization following China NDA acceptance for plaque psoriasis Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #junshibiosciences #fosunwanbang #roconkibart #plaquepsoriasis #monoclonalantibody #licensingdeal #pharma #immunology #dermatology #biotech https://lnkd.in/dgDP8pcS